Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
Cell Source (OTCQB:CLCS) presented groundbreaking preclinical findings at the 2024 American Society of Hematology Annual Meeting, demonstrating how their proprietary Veto Cell technology can overcome NK cell-mediated rejection in allogeneic cell therapy. The research shows Veto Tcm cells can suppress NK cell activity without triggering host T-cell proliferation or graft-versus-host disease by down-regulating the DNAM-1 activating receptor on NK cells.
This breakthrough could enable the development of off-the-shelf CAR-T therapies that are safer, more cost-effective, and scalable compared to existing treatments. The technology's ability to suppress NK-mediated rejection represents a significant advancement in addressing current cellular therapy limitations, particularly in facilitating safer mismatched donor stem cell and organ transplantation.
Cell Source (OTCQB:CLCS) ha presentato risultati preclinici innovativi al Meeting Annuale della Società Americana di Ematologia 2024, dimostrando come la loro tecnologia proprietaria Veto Cell possa superare il rigetto mediato dalle cellule NK nella terapia cellulare allogenica. La ricerca mostra che le cellule Veto Tcm possono sopprimere l'attività delle cellule NK senza innescare la proliferazione delle cellule T dell'ospite o la malattia del trapianto contro l'ospite, attraverso la down-regulation del recettore attivante DNAM-1 sulle cellule NK.
Questa scoperta potrebbe consentire lo sviluppo di terapie CAR-T pronte all'uso che siano più sicure, più cost-effective e scalabili rispetto ai trattamenti esistenti. La capacità della tecnologia di sopprimere il rigetto mediato dalle cellule NK rappresenta un avanzamento significativo nell'affrontare le attuali limitazioni delle terapie cellulari, in particolare nel facilitare trapianti di cellule staminali e organi da donatori incompatibili in modo più sicuro.
Cell Source (OTCQB:CLCS) presentó hallazgos preclínicos innovadores en la Reunión Anual de la Sociedad Americana de Hematología 2024, demostrando cómo su tecnología propietaria Veto Cell puede superar el rechazo mediado por células NK en la terapia celular alogénica. La investigación muestra que las células Veto Tcm pueden suprimir la actividad de las células NK sin desencadenar la proliferación de células T del huésped ni la enfermedad injerto contra huésped, al down-regular el receptor activador DNAM-1 en las células NK.
Este avance podría permitir el desarrollo de terapias CAR-T disponibles que sean más seguras, más rentables y escalables en comparación con los tratamientos existentes. La capacidad de la tecnología para suprimir el rechazo mediado por NK representa un avance significativo en la solución de las limitaciones actuales de la terapia celular, especialmente en la facilitación de trasplantes de células madre y órganos de donantes incompatibles de manera más segura.
셀 소스 (OTCQB:CLCS)는 2024 미국 혈액학회 연례 회의에서 혁신적인 전임상 결과를 발표했으며, 이들은 자사의 독점 기술인 베토 셀 기술이 동종세포 치료에서 NK 세포 매개 거부 반응을 극복할 수 있음을 보여주었습니다. 연구에 따르면 베토 Tcm 세포는 NK 세포의 DNAM-1 활성화 수용체를 하향 조절하여 숙주 T 세포의 증식이나 이식편 대 숙주병을 유발하지 않고 NK 세포의 활성을 억제할 수 있습니다.
이 혁신은 기존 치료법보다 더 안전하고 비용 효과적이며 확장 가능한 진열형 CAR-T 치료법의 개발을 가능하게 할 수 있습니다. NK 매개 거부 반응을 억제하는 기술의 능력은 특히 안전한 불일치 기증자 줄기 세포와 장기 이식의 촉진을 통해 현재 세포 치료의 한계를 해결하는 데 중요한 발전을 의미합니다.
Cell Source (OTCQB:CLCS) a présenté des résultats précliniques révolutionnaires lors de la Réunion Annuelle de la Société Américaine d'Hématologie 2024, démontrant comment leur technologie propriétaire Veto Cell peut surmonter le rejet médié par les cellules NK dans la thérapie cellulaire allogénique. La recherche montre que les cellules Veto Tcm peuvent supprimer l'activité des cellules NK sans déclencher la prolifération des cellules T de l'hôte ni la maladie du greffon contre l'hôte, en down-régulant le récepteur d'activation DNAM-1 sur les cellules NK.
Cette avancée pourrait permettre le développement de thérapies CAR-T prêtes à l'emploi qui sont plus sûres, plus rentables et évolutives par rapport aux traitements existants. La capacité de la technologie à supprimer le rejet médié par les cellules NK représente un progrès significatif dans la prise en charge des limitations actuelles de la thérapie cellulaire, en particulier pour faciliter des greffes de cellules souches et d'organes de donneurs incompatibles de manière plus sûre.
Cell Source (OTCQB:CLCS) präsentierte bahnbrechende präklinische Ergebnisse auf dem Jahreskongress der American Society of Hematology 2024 und zeigte, wie ihre proprietäre Veto Cell Technologie die NK-Zell-vermittelte Abstoßung in der allogenen Zelltherapie überwinden kann. Die Forschung zeigt, dass Veto Tcm-Zellen die Aktivität von NK-Zellen unterdrücken können, ohne die Proliferation von T-Zellen des Wirts oder die Transplantat-gegen-Wirt-Krankheit auszulösen, indem der aktivierende Rezeptor DNAM-1 auf NK-Zellen herunterreguliert wird.
Dieser Durchbruch könnte die Entwicklung von vorrätigen CAR-T-Therapien ermöglichen, die sicherer, kosteneffizienter und skalierbar im Vergleich zu bestehenden Behandlungen sind. Die Fähigkeit der Technologie, die NK-vermittelte Abstoßung zu unterdrücken, stellt einen bedeutenden Fortschritt bei der Bewältigung der aktuellen Begrenzungen der Zelltherapie dar, insbesondere bei der Erleichterung sicherer Transplantationen inkompatibler Stammzellen und Organe von Spendern.
- Demonstrated successful suppression of NK cell-mediated rejection in preclinical studies
- Technology shows potential for safer and more cost-effective off-the-shelf CAR-T therapies
- Novel mechanism discovered for enhancing allogeneic CAR-T therapies under mild conditioning regimens
- Results are still in preclinical stage, requiring further validation
- Potential conflicts of interest with lead researcher holding equity in company
Research Presented at the American Society of Hematology Annual Meeting Highlights New Mechanisms to Overcome Immune Rejection
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, recently presented promising preclinical findings at the 2024 American Society of Hematology (ASH) Annual Meeting. The research showcased how the company's proprietary Veto Cell technology can overcome one of the most critical barriers in allogeneic cell therapy - natural killer (NK) cell-mediated rejection. This innovation brings the field closer to realizing off-the-shelf CAR-T therapies, which can be safer, less costly and more scalable than existing allogeneic CAR-T.
The study, titled "Overcoming NK Cell-Mediated Allograft Rejection by Anti-Third Party Central Memory Veto CD8 T Cells through Down-Regulation of the Activating Receptor DNAM-1 on Alloreactive NK Cells," highlights the ability of Veto Tcm cells to suppress NK cell activity without triggering host T-cell proliferation or graft-versus-host disease (GvHD). By down-regulating the DNAM-1 activating receptor on NK cells, facilitated by the DNAM-1 ligand CD155, Cell Source has demonstrated a novel pathway to enhance the safety and efficacy of allogeneic CAR-T therapies under mild conditioning regimens.
See link below for abstract:
https://ash.confex.com/ash/2024/webprogram/Paper203601.html
Research Highlights:
NK Cell Suppression: Veto Cells effectively suppress NK-mediated rejection.
Distinct Mechanism: The approach involves selective modulation of DNAM-1 on NK cells without causing adverse effects.
Broader Application: Results suggest potential for safer and more accessible cellular therapies for hematologic malignancies and other conditions.
Advancing the Allogeneic CAR-T Therapy Landscape
These findings underscore Cell Source's commitment to addressing the limitations of current cellular therapies. The ability to suppress NK-mediated rejection is a key advancement in enabling off-the-shelf CAR-T therapy, supporting the potential to overcome scalability, logistics and cost challenges associated with autologous approaches. The results also align with Cell Source's broader vision of advancing immune tolerance to facilitate safer mismatched donor stem cell transplants and pioneer mismatched donor organ transplantation.
Quote from Dr. Yair Reisner:
"Our results help to unravel the mechanism by which anti-viral CD8 central memory veto cells overcome NK-mediated rejection of mismatched hemopoietic transplants," said study lead Dr. Yair Reisner, Professor of Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center. "These findings represent a significant step toward overcoming barriers in the development of off-the-shelf CAR T cell therapies, an important area of focus within the field of cancer immunotherapy."
Disclosure
Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee in accordance with institution policy.
About Veto Cell Technology
Cell Source's Veto Cell technology is the brainchild of Professor Yair Reisner, a world-renowned expert in immune tolerance management who pioneered mismatched bone marrow transplants. The company's technology, exclusively licensed from The Weizmann Institute of Science in Israel, is being developed to create safer, donor-derived CAR-T therapy and improve the accessibility of stem cell transplants and organ transplants.
About Cell Source, Inc.
Cell Source, Inc. (OTCQB:CLCS) is the worldwide, exclusive innovator of Veto Cell-based cellular therapy and immunotherapy platform technologies designed to provide safer and more accessible stem cell (e.g. bone marrow) transplantation and improve the treatment of blood cancers such as leukemia, lymphoma and multiple myeloma. The company licenses the technology from The Weizmann Institute of Science in Israel and sponsors both research and clinical development projects at MD Anderson Cancer Center . In addition, its Veto Cell platform is being developed to reverse sickle cell disease and other non-malignant genetic blood disorders and to durably treat auto immune diseases such as type 1 diabetes. The Company is developing a Veto Cell CAR-T platform which could potentially enable CAR-T therapy to be used in donor-derived (allogeneic) settings with increased safety, efficacy, and persistence. Cell Source's Veto Cell technologies are also being developed to facilitate safer, donor mismatched organ transplants (e.g., kidney and liver) and also avoid the current need for life-long daily immune system suppression.
The Company is focused on transitioning this allogeneic Veto Cell platform into additional clinical trials in order to develop safe and curative cell therapy treatments (such as stem cell transplants) from mismatched donors as well as safe, durable, and efficacious "off-the-shelf" immunotherapy and immuno-oncology products.
For more information, visit cell-source.com.
Investor Contact
Itamar Shimrat, CEO
646.416.7896
ishimrat@cell-source.com
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on June 6, 2024. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact Information
Brendan Rempel
brendan@alternativeadvisory.com
SOURCE: Cell Source, Inc.
View the original press release on accesswire.com
FAQ
What breakthrough did Cell Source (CLCS) present at the 2024 ASH Annual Meeting?
How does CLCS's Veto Cell technology work to prevent rejection?
What are the potential benefits of CLCS's off-the-shelf CAR-T therapy?
What is the current development stage of CLCS's Veto Cell technology?
